Inovio Pharmaceuticals (INO) EBT Margin (2010 - 2025)

Inovio Pharmaceuticals has disclosed EBT Margin across 16 years of filings, most recently posting 38315.02% for Q1 2025.

• In Q1 2025, EBT Margin changed N/A year-over-year to 38315.02%; the TTM figure through Dec 2025 stood at 130382.25% (down 7955606.0% YoY), while the FY2025 annual figure was 129167.54%, down 7965810.0% from the prior year.
• EBT Margin came in at 38315.02% for Q1 2025 at Inovio Pharmaceuticals, down from 16682.03% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 412.75% in Q3 2022 to a low of 43687.24% in Q4 2022.
• Average EBT Margin over 5 years is 23115.04%, with a median of 20627.17% recorded in 2021.
• The largest YoY upside for EBT Margin was 2021442 bps in 2022 against a maximum downside of 3094196 bps in 2022.
• Over 5 years, EBT Margin stood at 12745.28% in 2021, then tumbled by 243 bps to 43687.24% in 2022, then soared by 44 bps to 24357.91% in 2023, then surged by 32 bps to 16682.03% in 2024, then tumbled by 130 bps to 38315.02% in 2025.
• Per Business Quant data, the three most recent EBT Margin figures were 38315.02% in Q1 2025, 16682.03% in Q4 2024, and 32959.09% in Q2 2024.